• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Graybug Vision downgraded by Needham

    5/13/21 6:13:16 AM ET
    $GRAY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRAY alert in real time by email
    Needham downgraded Graybug Vision from Buy to Hold
    Get the next $GRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRAY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Graybug Vision downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Graybug Vision from Outperform to Market Perform and set a new price target of $5.00 from $23.00 previously

      5/13/21 7:17:20 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Graybug Vision downgraded by Needham

      Needham downgraded Graybug Vision from Buy to Hold

      5/13/21 6:13:16 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Graybug Vision with a new price target

      SVB Leerink reiterated coverage of Graybug Vision with a rating of Outperform and set a new price target of $23.00 from $45.00 previously

      3/15/21 8:09:07 AM ET
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care